Autonomix Medical, Inc.

Equities

AMIX

US05330T1060

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
2.5 USD -0.79% Intraday chart for Autonomix Medical, Inc. -13.49% 0.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Autonomix Enters into Agreement with Noisefigure Research, Inc. to Develop Next Generation of Its Proprietary Microchip CI
Autonomix Medical Secures US Patent for Catheter-Based Technology to Treat Cancer-Related Pain MT
Autonomix Medical, Inc. Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation CI
Autonomix Appoints Jennifer Cook as Chief Business Officer CI
Autonomix Medical, Inc.(NasdaqCM:AMIX) added to S&P TMI Index CI
Autonomix Medical, Inc. Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market CI
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market CI
Autonomix Medical, Inc. Secures Principal Investigators and Completes Clinical Training for First Human Study CI
Autonomix Medical, Inc. Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market CI
Autonomix Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Earnings Overshadow Potential Bond Surge Concerns MT
Top Premarket Gainers MT
Autonomix Gets Approval to Start Clinical Trial for Pancreatic Cancer Pain Treatment in Uzbekistan MT
Autonomix Re-Acquires Sensing Technology from Impulse Medical for $8 Million in Stock MT
Autonomix Medical, Inc.(NasdaqCM:AMIX) added to NASDAQ Composite Index CI
Autonomix Medical, Inc. Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Chart Autonomix Medical, Inc.
More charts
Autonomix Medical, Inc. is a medical device company, which is focused on advancing technologies to treat diseases involving the peripheral nervous system. Its technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate peripheral neural signals with up to 1,000 times sensitivity. It is developing a two-fold technology that can both detect malfunctioning neural signals and ablate nerves in one simple procedure for pain management. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation, and chronic pain management across a disease spectrum. Its Autonomix catheter is equipped with a microchip that converts analog signals from the body to a digital signal that can be sent directly to a computer screen.
More about the company
  1. Stock Market
  2. Equities
  3. AMIX Stock
  4. News Autonomix Medical, Inc.
  5. Autonomix Medical Secures US Patent for Catheter-Based Technology to Treat Cancer-Related Pain
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW